Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT)
<p><strong>Background:</strong> Sickle cell anaemia (SCA) has historically been associated with high levels of childhood mortality in Africa. Although malaria has a major contribution to this mortality, to date, the clinical pathology of malaria among children with SCA has been poo...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2022
|
| _version_ | 1826308254688346112 |
|---|---|
| author | Uyoga, S Olupot-Olupot, P Connon, R Kiguli, S Opoka, RO Alaroker, F Muhindo, R Macharia, A Dondorp, A Gibb, DM Walker, AS George, EC Maitland, K Williams, TN |
| author_facet | Uyoga, S Olupot-Olupot, P Connon, R Kiguli, S Opoka, RO Alaroker, F Muhindo, R Macharia, A Dondorp, A Gibb, DM Walker, AS George, EC Maitland, K Williams, TN |
| author_sort | Uyoga, S |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Sickle cell anaemia (SCA) has historically been associated with high levels of childhood mortality in Africa. Although malaria has a major contribution to this mortality, to date, the clinical pathology of malaria among children with SCA has been poorly described. We aimed to explore the relationship between SCA and Plasmodium falciparum malaria in further detail by investigating the burden and severity of malaria infections among children recruited with severe anaemia to the TRACT trial of blood transfusion in Africa.</p>
<p><strong>Methods:</strong> This study is a post-hoc secondary analysis of the TRACT trial data, conducted after trial completion. TRACT was an open-label, multicentre, factorial, randomised controlled trial enrolling children aged 2 months to 12 years who presented with severe anaemia (haemoglobin <6·0 g/dL) to four hospitals in Africa. This secondary analysis is restricted to Uganda, where the birth prevalence of SCA is approximately 1% and malaria transmission is high. Children were classified as normal (HbAA), heterozygous (HbAS), or homozygous (HbSS; SCA) for the rs334 A→T sickle mutation in HBB following batch-genotyping by PCR at the end of the trial. To avoid confounding from SCA-specific medical interventions, we considered children with an existing diagnosis of SCA (known SCA) separately from those diagnosed at the end of the trial (unknown SCA). The outcomes considered in this secondary analysis were measures of P falciparum parasite burden, features of severe malaria, and mortality at day 28 in malaria-positive children.</p>
<p><strong>Findings:</strong> Between Sept 17, 2014, and May 15, 2017, 3944 children with severe anaemia were enrolled into the TRACT trial. 3483 children from Uganda were considered in this secondary analysis. Overall, 1038 (30%) of 3483 Ugandan children had SCA. 1815 (78%) of 2321 children without SCA (HbAA) tested positive for P falciparum malaria, whereas the prevalence was significantly lower in children with SCA (347 [33%] of 1038; p<0·0001). Concentrations of plasma P falciparum histidine-rich protein 2 (PfHRP2), a marker of the total burden of malaria parasites within an individual, were significantly lower in children with either known SCA (median 8 ng/mL; IQR 0–57) or unknown SCA (7 ng/mL; 0–50) than in HbAA children (346 ng/mL; 21–2121; p<0·0001). In contrast to HbAA children, few HbSS children presented with classic features of severe and complicated malaria, but both the frequency and severity of anaemia were higher in HbSS children. We found no evidence for increased mortality at day 28 in those with SCA compared with those without SCA overall (hazard ratios 1·07 [95% CI 0·31–3·76] for known SCA and 0·67 [0·15–2·90] for unknown SCA).</p>
<p><strong>Interpretation:</strong> The current study suggests that children with SCA are innately protected against classic severe malaria. However, it also shows that even low-level infections can precipitate severe anaemic crises that would likely prove fatal without rapid access to blood transfusion services.</p> |
| first_indexed | 2024-03-07T07:16:49Z |
| format | Journal article |
| id | oxford-uuid:6dd647b0-119a-4202-b803-b80244220aa1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:16:49Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:6dd647b0-119a-4202-b803-b80244220aa12022-08-16T08:27:10ZSickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6dd647b0-119a-4202-b803-b80244220aa1EnglishSymplectic ElementsElsevier2022Uyoga, SOlupot-Olupot, PConnon, RKiguli, SOpoka, ROAlaroker, FMuhindo, RMacharia, ADondorp, AGibb, DMWalker, ASGeorge, ECMaitland, KWilliams, TN<p><strong>Background:</strong> Sickle cell anaemia (SCA) has historically been associated with high levels of childhood mortality in Africa. Although malaria has a major contribution to this mortality, to date, the clinical pathology of malaria among children with SCA has been poorly described. We aimed to explore the relationship between SCA and Plasmodium falciparum malaria in further detail by investigating the burden and severity of malaria infections among children recruited with severe anaemia to the TRACT trial of blood transfusion in Africa.</p> <p><strong>Methods:</strong> This study is a post-hoc secondary analysis of the TRACT trial data, conducted after trial completion. TRACT was an open-label, multicentre, factorial, randomised controlled trial enrolling children aged 2 months to 12 years who presented with severe anaemia (haemoglobin <6·0 g/dL) to four hospitals in Africa. This secondary analysis is restricted to Uganda, where the birth prevalence of SCA is approximately 1% and malaria transmission is high. Children were classified as normal (HbAA), heterozygous (HbAS), or homozygous (HbSS; SCA) for the rs334 A→T sickle mutation in HBB following batch-genotyping by PCR at the end of the trial. To avoid confounding from SCA-specific medical interventions, we considered children with an existing diagnosis of SCA (known SCA) separately from those diagnosed at the end of the trial (unknown SCA). The outcomes considered in this secondary analysis were measures of P falciparum parasite burden, features of severe malaria, and mortality at day 28 in malaria-positive children.</p> <p><strong>Findings:</strong> Between Sept 17, 2014, and May 15, 2017, 3944 children with severe anaemia were enrolled into the TRACT trial. 3483 children from Uganda were considered in this secondary analysis. Overall, 1038 (30%) of 3483 Ugandan children had SCA. 1815 (78%) of 2321 children without SCA (HbAA) tested positive for P falciparum malaria, whereas the prevalence was significantly lower in children with SCA (347 [33%] of 1038; p<0·0001). Concentrations of plasma P falciparum histidine-rich protein 2 (PfHRP2), a marker of the total burden of malaria parasites within an individual, were significantly lower in children with either known SCA (median 8 ng/mL; IQR 0–57) or unknown SCA (7 ng/mL; 0–50) than in HbAA children (346 ng/mL; 21–2121; p<0·0001). In contrast to HbAA children, few HbSS children presented with classic features of severe and complicated malaria, but both the frequency and severity of anaemia were higher in HbSS children. We found no evidence for increased mortality at day 28 in those with SCA compared with those without SCA overall (hazard ratios 1·07 [95% CI 0·31–3·76] for known SCA and 0·67 [0·15–2·90] for unknown SCA).</p> <p><strong>Interpretation:</strong> The current study suggests that children with SCA are innately protected against classic severe malaria. However, it also shows that even low-level infections can precipitate severe anaemic crises that would likely prove fatal without rapid access to blood transfusion services.</p> |
| spellingShingle | Uyoga, S Olupot-Olupot, P Connon, R Kiguli, S Opoka, RO Alaroker, F Muhindo, R Macharia, A Dondorp, A Gibb, DM Walker, AS George, EC Maitland, K Williams, TN Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title | Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title_full | Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title_fullStr | Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title_full_unstemmed | Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title_short | Sickle cell anaemia and severe P. falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT) |
| title_sort | sickle cell anaemia and severe p falciparum malaria a secondary analysis of the transfusion and treatment of african children trial tract |
| work_keys_str_mv | AT uyogas sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT olupotolupotp sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT connonr sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT kigulis sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT opokaro sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT alarokerf sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT muhindor sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT machariaa sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT dondorpa sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT gibbdm sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT walkeras sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT georgeec sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT maitlandk sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract AT williamstn sicklecellanaemiaandseverepfalciparummalariaasecondaryanalysisofthetransfusionandtreatmentofafricanchildrentrialtract |